Avoid Errors With the New Monoclonal Antibodies for COVID-19
Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.
These new monoclonal antibodies, or "mabs," block the virus that causes COVID-19...SARS-CoV-2...from entering cells.
Both meds are single-dose IV infusions given over 1 hour.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote